Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has issued an update.
Qyuns Therapeutics Co., Ltd. announced the acceptance of its marketing authorization application for its Ustekinumab Injection, a biosimilar of Stelara, targeted for use in treating moderate-to-severe Crohn’s disease. This acceptance marks a significant step for the company in expanding its product offerings within the therapeutic biological products market, potentially enhancing its competitive positioning and providing stakeholders with new opportunities in the pharmaceutical industry.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a Chinese joint stock company operating in the pharmaceutical industry. The company primarily focuses on the development and distribution of biosimilar drugs, with a particular emphasis on treatments for immune-mediated inflammatory diseases.
YTD Price Performance: 0.41%
Average Trading Volume: 52,423
Technical Sentiment Consensus Rating: Strong Buy
For detailed information about 2509 stock, go to TipRanks’ Stock Analysis page.